Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: Results from an open-label 6-month clinical trial

Sleep

Volumn 27, Issue 4, 2004, Pages 674-682

  Beneš, Heike ^a   Heinrich, Claus R ^b   Ueberall, Michael A ^c   Kohnen, Ralf ^b  

^a HELIOS KLINIKEN SCHWERIN   (Germany)

^b Biometrics GmbH   (Germany)

^c Institute for Neurological Sciences Algesiology and Pediatrics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CABERGOLINE; CAPTOPRIL; CARBAMAZEPINE; DOMPERIDONE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; HYPNOTIC AGENT; LEVODOPA; MOLSIDOMINE; PERGOLIDE; PRAMIPEXOLE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DREAMING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; HYPERKINESIA; HYPERTENSION; HYPOTENSION; IDIOPATHIC DISEASE; ISCHEMIC HEART DISEASE; LIMB PAIN; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NIGHT; OPEN STUDY; OUTCOMES RESEARCH; PATIENT SATISFACTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SLEEP; SLEEP DISORDER; SYMPTOM; TITRIMETRY; WEIGHT GAIN;

EID: 3042524445     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/27.4.674     Document Type: Article

References (40)

1. Hening WA, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999;22:970-98.
2. Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002;58 Suppl 1:87-92.
3. Stiasny K, Wetter TC, Trenkwalder C, Oertel WH. Restless legs syndrome and its treatment by dopamine agonists. Parkinsonism Relat Disord 2000;7:21-5.
4. Weimerskirch PR, Ernst ME. Newer dopamine agonists in the treatment of restless legs syndrome. Ann Pharmacother 2001;35:627-30.
5. Tan EK, Ondo W. Restless legs syndrome: clinical features and treatment. Am J Med Sci 2000;319:397-403.
6. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
7. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-8.
8. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa in uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-8.
9. Beneš H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073-81.
10. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-90.
11. Walters AS, Hening WA, Chokroverty S, Gidro-Franck S. A double blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-8.
12. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-50.
13. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-43.
14. Stiasny K, Robbecke J, Schuler P, Oertel WH. Treatment of idio-pathic restless legs syndrome (RLS) with the D2-agonist cabergo-line-an open clinical trial. Sleep 2000;23:349-54.
15. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000;41:181-9.
16. Saletu M, Anderer P, Saletu B, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology. 2000;41:190-9.
17. Evidente VG. Piribedil for restless legs syndrome: a pilot study. Mov Disord 2001;16:579-81.
18. Tergau F, Wischer S, Wolf C, Paulus W. Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine. Mov Disord 2001;16:731-5.
19. Von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990;47:1223-4.
20. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993;16:713-6.
21. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;119:205-13.
22. Trenkwalder C, Collado Seidel V, et al. One-year treatment with standard and sustained-release levodopa-appropriate long-term treat-ment in the restless legs syndrome? Mov Disord 2003;18:1184-9.
23. Staedt J, Hunerjager H, Ruther E, Stoppe G. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). Long-term follow up on pergolide. J Neural Transm 1998;105:265-8.
24. Stiasny K, Wetter TC, Winkelmann J, et al. Long-term effects of per-golide in the treatment of restless legs syndrome. Neurology 2001;56:1399-402.
25. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7Suppl 1:27-31.
26. Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002;252:185-94.
27. Ferrini-Strambi L, Oldani A, Castronova V, Zucconi M. Long-term treatment for restless legs syndrome with pramipexole: augmentation effect findings. Sleep 2001;24:A362.
28. Winkelman J, Bennett S. Augmentation with pramipexole in the long-term treatment of restless legs syndrome. Sleep 2002;25;A253.
29. Guilleminault C, Cetel C, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445.
30. Marco AD, Appiah-Kubi LS, Chaudhuri KR. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother. 2002;3:1481-7.
31. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 2003;12:1335-52.
32. Walters AS. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-42.
33. Fariello RG. Pharmocodynamic and pharmacokinetic features of cabergoline. Drugs 1997;55Suppl2:10-6.
34. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose response and duration of effect. Clin Neuropharmacol 1996;19:202-12.
35. Stiasny K, Roebbecke J, Schueler P, Oertel WH. Treatment of restless legs syndrome (RLS) with cabergoline. J Neurol 1998;245:405.
36. Stiasny-Kolster K, Ueberall M, Oertel WH for the German Cabergoline RLS Study Group. Cabergoline in advanced RLS: a double-blind, placebo-controlled multicenter trial. Mov Disord 2002;17 Suppl5:S231.
37. The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32.
38. Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003;4:95-7.
39. Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C. Severity rating of restless legs syndrome: review of ten years experience with the RLS-6 scales in clinical trials. Sleep 2003;26:A342.
40. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109-17.